Fundraising Fox

Jake Nunn

Investor

Partner at SR One Capital Management · Board director at Dermira · Board director at Trivascular · Director at Addex Therapeutics

San Francisco Bay Area

Writes $50K – $50M checks · typically $25M

Find your path to Jake

330 people in our graph share verified history with Jake — schools, employers, funds. One of them is your warm intro.

Crystal HuangunlockedJake: together at New Enterprise Associates (NEA) (2018–2021)
×4Jake: together at New Enterprise Associates (NEA)
Jake: together at SR One Capital Management
×2Jake: together at Mpmcapital

About

Jake Nunn is a Partner at SR One focusing on later-stage private and public biotech investments, with over 25 years in the life sciences industry as an investor, board director, research analyst, and investment banker. He was previously an investing partner at New Enterprise Associates (NEA) from 2006 to 2019, where he founded the firm's public healthcare investing practice, and earlier held roles at MPM Capital, Franklin Templeton Investments, and Alex. Brown & Sons. He holds an MBA from Stanford Graduate School of Business and a BA in Economics from Dartmouth College, and is a CFA charterholder.

Contact· self-published, not guessed

Invests in

Biotech

Board director at Dermira

Intro paths

In turn, Jake can intro founders to Dermira's investors below.

Co-founders at Dermira

TG
Thomas G. WiggansExecutive Officer, Director
EA
Eugene A. BauerExecutive Officer, Director

Board director at Trivascular

Intro paths

In turn, Jake can intro founders to Trivascular's investors below.

Co-founders at Trivascular

MVMichael V. Chobotov
Michael V. ChobotovExecutive Officer

Director at Addex Therapeutics

Intro paths

In turn, Jake can intro founders to Addex Therapeutics's investors below.

Experience

  1. SR One Capital ManagementPartnercurrent2024 — presentSan Francisco Bay Area
  2. SR One Capital ManagementVenture Partner2023 — 2024San Francisco Bay Area
  3. Zenas BioPharmaBoard Membercurrent2024 — presentWaltham, Massachusetts, United States
  4. Regulus TherapeuticsBoard Membercurrent2019 — presentSan Diego, California
  5. Addex TherapeuticsBoard Membercurrent2018 — presentGeneva, Switzerland
  6. Humanetics CorporationBoard Membercurrent2022 — presentMinneapolis, Minnesota, United States
  7. Trevena, Inc.Board Member2013 — 2024Chesterbrook, Pennsylvania
  8. Hexima Limited (ASX:HXL)Board Member2021 — 2023Melbourne, Victoria, Australia
  9. New Enterprise Associates (NEA)Venture Advisor2019 — 2022
  10. New Enterprise Associates (NEA)Partner2006 — 2018
  11. Oventus Medical LtdBoard Member2020 — 2022Brisbane, Queensland, Australia
  12. Qool TherapeuticsBoard Member2019 — 2021Mountain View, CA
  13. Dermira, Inc.Board Member2011 — 2020Menlo Park, California
  14. TriVascular, IncBoard Member2008 — 2016Santa Rosa, California
  15. Hyperion TherapeuticsBoard Member2009 — 2015South San Francisco, California
  16. Transcept Pharmaceuticals, Inc.Board Member2009 — 2014Richmond, California
  17. MPM CapitalPartner2001 — 2006
  18. Franklin Templeton InvestmentsPortfolio Manager1998 — 2000
  19. Alex. Brown & SonsAnalyst1994 — 1996San Francisco, California
  20. GEFinancial Analyst1992 — 1994San Jose, California

Skills & more

Venture Capital35Private Equity17Due Diligence22Mergers1Medical Devices5PharmaceuticalsBiotechnology5Investments9CFAHedge Funds3Mutual Funds
  • Chartered Financial Analyst (CFA)CFA Institute

From Jake's professional profile.

Deals · 4

Addex TherapeuticsBoard seat

via SR One Capital Management · filed Apr 2023 · $3.7M raise

Regulus Therapeutics Inc.Board seat

via SR One Capital Management · filed Dec 2021 · $34.6M raise

DermiraBoard seat

via SR One Capital Management · filed Dec 2018 · $1M raise

TrivascularBoard seat

via SR One Capital Management · filed Aug 2015 · $10M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Hyperion TherapeuticsRegulus TherapeuticsZenas BiopharmaZenas Biopharma

Sources: the firm's website · SEC Form D filings.

Colleagues at SR One Capital Management

Network3

Investors connected to Jake in public investor directories — a warm-intro map.

Frequently asked questions

Who is Jake Nunn?
Jake Nunn is a Partner at SR One focusing on later-stage private and public biotech investments, with over 25 years in the life sciences industry as an investor, board director, research analyst, and investment banker. He was previously an investing partner at New Enterprise Associates (NEA) from 2006 to 2019, where he founded the firm's public healthcare investing practice, and earlier held roles at MPM Capital, Franklin Templeton Investments, and Alex. Brown & Sons. He holds an MBA from Stanford Graduate School of Business and a BA in Economics from Dartmouth College, and is a CFA charterholder.
Where does Jake Nunn work?
Jake Nunn is Partner at SR One Capital Management and Board director at Dermira and Board director at Trivascular.
What does Jake Nunn invest in?
Jake Nunn invests in Biotech.
What check size does Jake Nunn write?
Jake Nunn typically writes checks of $50K – $50M.
What boards does Jake Nunn sit on?
Jake Nunn holds tracked board seats at Addex Therapeutics, Addex Therapeutics, Dermira, Dermira, Hyperion Therapeutics, Regulus Therapeutics, Regulus Therapeutics Inc., Trivascular, Zenas Biopharma, Zenas Biopharma.
Where did Jake Nunn go to school?
Jake Nunn studied at Stanford University Graduate School of Business (Master of Business Administration (MBA)); Dartmouth College (Bachelor of Arts (B.A.), Economics); Executive Education / Stanford Graduate School of Business (Directors' Consortium).

Same school

Shared employers